Intracerebroventricular liraglutide protected against sepsis-associated brain damage in mice by reducing neuronal loss, suppressing glial cell activation, and restoring mitochondrial function via AKT/STAT3 signaling.
Neurological scores improved through day 5Liraglutide-treated septic mice showed reduced neurological impairment alongside preserved hippocampal neurons and suppressed brain immune activation
What the researchers found
Intracerebroventricular liraglutide administered 1 hour before cecal ligation and puncture (CLP) alleviated neurological impairment scores and reduced glial cell activation, neuronal loss, and neurodegeneration in the hippocampus of septic mice. In vitro, liraglutide suppressed neuron-microglia interaction under LPS stimulation. Liraglutide also inhibited mitochondrial damage and oxidative stress in hippocampal neurons. The mechanism involved restoring diminished p-AKT levels while reversing STAT3 phosphorylation in hippocampal neurons. Neurological severity scores, weight loss, food intake, and survival were monitored for up to 5 days post-CLP.
Why it matters
Sepsis-associated encephalopathy affects up to 70% of ICU sepsis patients and is linked to increased mortality and long-term cognitive disability. No targeted treatment exists — management is limited to treating the underlying infection. Liraglutide is already approved and widely used, making it an attractive candidate for repurposing. Demonstrating neuroprotective effects in sepsis adds to the expanding evidence of GLP-1 drugs' benefits beyond metabolism.
How the study worked
Male C57BL/6J mice were divided into three groups: CLP (sepsis model), CLP + liraglutide (intracerebroventricular), and sham operation. Liraglutide was administered 1 hour before CLP surgery. Brain tissue was analyzed by immunohistochemistry, transmission electron microscopy, and Western blot at day 1 post-CLP. Modified neurological severity scores were assessed at days 0, 1, 3, and 5. In vitro experiments used BV2 microglial cells and HT22 hippocampal neurons to assess neuron-microglia interactions under LPS stimulation.
What this study cannot tell us
Liraglutide was delivered directly into the brain (intracerebroventricularly), which is not a practical clinical route — it's unclear whether systemic injection would achieve the same brain concentrations. The drug was given pre-treatment (1 hour before CLP), whereas clinical use would need to work after sepsis onset. Small animal numbers typical of mouse studies limit statistical power. Only male mice were studied, and sex differences in sepsis outcomes are well-documented.
How to read the evidence
This is a preclinical mouse study using a standard sepsis model (CLP) with both in vivo and in vitro components. The mechanistic depth (AKT/STAT3 signaling, mitochondrial function, neuron-microglia interactions) is strong, but the intracerebroventricular delivery route limits clinical translatability.
When this study was published
Published in 2026, this is very recent research extending GLP-1 neuroprotection evidence to the critical care setting of sepsis-associated encephalopathy.
The bigger picture
GLP-1 receptor agonists are accumulating evidence for neuroprotection across multiple conditions — Alzheimer's disease, Parkinson's disease, stroke, traumatic brain injury, and now sepsis-associated encephalopathy. The common thread is protection of brain mitochondria and suppression of neuroinflammation, suggesting GLP-1 signaling activates a broad neuroprotective program. If these preclinical findings translate, GLP-1 drugs could become part of the ICU toolkit for protecting the brain during critical illness.
Questions still open
- Can systemically administered liraglutide or semaglutide cross the blood-brain barrier sufficiently to protect against sepsis-associated encephalopathy?
- Would post-sepsis administration of GLP-1 drugs still provide neuroprotection, since pre-treatment isn't clinically feasible?
- Do ICU patients already on GLP-1 drugs have better neurological outcomes during sepsis?
Common questions
What is sepsis-associated encephalopathy and why is it dangerous?
How does liraglutide protect the brain during sepsis?
Read the original research
Liraglutide alleviates sepsis-associated encephalopathy via attenuating neuronal damage, glial cell activation and mitochondrial dysfunction in a mouse model of sepsis.
European journal of medical research, 31(1)
Citation
Li, Xiaoming; Wang, Jun; Zhang, Rongji; He, Haoran; Wang, Linjue; Wang, Yuliang; Yi, Hongyu. (2026). Liraglutide alleviates sepsis-associated encephalopathy via attenuating neuronal damage, glial cell activation and mitochondrial dysfunction in a mouse model of sepsis.. European journal of medical research, 31(1). https://doi.org/10.1186/s40001-026-03974-0